期刊
AMERICAN JOURNAL OF KIDNEY DISEASES
卷 68, 期 3, 页码 402-413出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2016.03.414
关键词
Chronic kidney disease (CKD); end-stage kidney disease (ESKD); patient outcomes; dialysis; treatment options; international comparisons; geographic variation; practice patterns; practice variation; transition to ESKD; renal outcome; nephrology care; nephrology clinic; CKDopps
资金
- European Renal Association-European Dialysis and Transplant Association
- Keryx
- Genzyme
- Hexal
- AbbVie
- Sanofi Renal
- Shire
- Vifor Fresenius Renal Pharma
- Japanese Society
- WiNe Institute
- Society for Nephrology in Germany
- Society for Nephrology in Italy
- Society for Nephrology in Spain
- Agence Nationale de la Recherche [ANR-10-COH0-01]
- Programme Hospitalier de Recherche Clinique
- Amgen
- Baxter
- Fresenius Medical Care
- GlaxoSmithKline
- Merck Sharp
- Dohme-Chibret
- Lilly
- Otsuka
- Vifor Fresenius Medical Care Pharma
- Japan Agency for Medical Research and Development (AMED)
- Jansen
- Astra Zeneca
- Novartis
- FMC
- Kyowa Hakko Kirin
- Baxter Healthcare
- WiNe (Wissenschaftliches Institut fur Nephrologe) of the Verband Deutsche Nierenzentren
Background: Minimizing clinical complications in patients with advanced chronic kidney disease (CKD) and improving the transition to dialysis therapy and transplantation represents a challenge, requiring reliable evidence regarding the effects of CKD care on outcomes. Study Design: The CKD Outcomes and Practice Patterns Study (CKDopps) is a new international prospective cohort study designed to describe and evaluate variation in nephrologist-led CKD practices. Setting & Participants: CKDopps is underway in Brazil, France, Germany, Japan, and the United States. Diverse national samples of nephrology clinics are being recruited based on random selection stratified by geographic region and clinic characteristics. CKDopps aims to enroll 12,200 non-dialysis-dependent patients with CKD (75% and 25% with estimated glomerular filtration rates < 30 and 30-<60 mL/min/1.73 m(2), respectively) to be followed up for 3 to 5 years. Predictors: Demographic, comorbid condition, laboratory, and treatment-related variables are collected at 6-month intervals; patient-reported data are collected annually and more frequently near the transition to end-stage kidney disease; nephrologist practice surveys are collected annually. Outcomes: Outcomes include mortality, end-stage kidney disease, other clinical events (eg, acute kidney injury, hospitalizations, infections, cardiovascular events, and transplant wait-listing), and patient-reported outcomes. Results: For the targeted sample size of 12,200 patients and 160 clinics, CKDopps has 80% power to detect HRs of 1.31 for mortality and 1.19 for mortality or transition to end-stage kidney disease. Limitations: CKDopps does not capture care provided in settings outside nephrology clinics (eg, primary care) or patients with CKD not receiving medical care. Conclusions: CKDopps is designed to characterize nephrology clinic practice variation and identify practices associated with better outcomes, with particular focus on advanced CKD, transition to end-stage kidney disease, and the patient experience. Because data will be collected during routine clinical care in real-world practice, analyses may yield practical readily implementable findings. CKDopps aims to establish a multinational infrastructure for research, collaboration, and ancillary investigation. Additional countries are encouraged to join. (C) 2016 by the National Kidney Foundation, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据